Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer.

IF 2.5 Q2 RESPIRATORY SYSTEM Tuberculosis and Respiratory Diseases Pub Date : 2024-10-01 Epub Date: 2024-05-14 DOI:10.4046/trd.2023.0190

Da Hyun Kang, Chang-Min Choi, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim, Seong Hoon Yoon, Yoonjoo Kim, Jeong Eun Lee

{"title":"Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer.","authors":"Da Hyun Kang, Chang-Min Choi, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim, Seong Hoon Yoon, Yoonjoo Kim, Jeong Eun Lee","doi":"10.4046/trd.2023.0190","DOIUrl":null,"url":null,"abstract":"Background: The use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer is increasing. Despite ongoing studies to predict the efficacy of ICIs, its use in clinical practice remains difficult. Thus, we aimed to discover a predictive marker by analyzing blood cell characteristics and developing a scoring system for patients treated with ICIs.Methods: This was a prospective multicenter study in patients with advanced nonsmall cell lung cancer (NSCLC) who received ICIs as second-line treatment from June 2021 to November 2022. Blood cell parameters in routine blood samples were evaluated using an automated hematology analyzer. Immune checkpoint inhibitor score (IChIS) was calculated as the sum of neutrophil count score and immature granulocyte score.Results: A total of 143 patients from four institutions were included. The treatment response was as follows: partial response, 8.4%; stable disease, 37.1%; and progressive disease, 44.8%. Median progression-free survival and overall survival after ICI treatment was 3.0 and 8.3 months, respectively. Median progression-free survival in patients with an IChIS of 0 was 4.0 months, which was significantly longer than 1.9 months in patients with an IChIS of 1 and 1.0 month in those with an IChIS of 2 (p=0.001). The median overall survival in patients with an IChIS of 0 was 10.2 months, which was significantly longer than 6.8 and 1.8 months in patients with an IChIS of 1 and 2, respectively (p<0.001).Conclusion: Baseline IChIS could be a potential biomarker for predicting survival benefit of immunotherapy in NSCLC.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"483-493"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468437/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Respiratory Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4046/trd.2023.0190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer is increasing. Despite ongoing studies to predict the efficacy of ICIs, its use in clinical practice remains difficult. Thus, we aimed to discover a predictive marker by analyzing blood cell characteristics and developing a scoring system for patients treated with ICIs.

Methods: This was a prospective multicenter study in patients with advanced nonsmall cell lung cancer (NSCLC) who received ICIs as second-line treatment from June 2021 to November 2022. Blood cell parameters in routine blood samples were evaluated using an automated hematology analyzer. Immune checkpoint inhibitor score (IChIS) was calculated as the sum of neutrophil count score and immature granulocyte score.

Results: A total of 143 patients from four institutions were included. The treatment response was as follows: partial response, 8.4%; stable disease, 37.1%; and progressive disease, 44.8%. Median progression-free survival and overall survival after ICI treatment was 3.0 and 8.3 months, respectively. Median progression-free survival in patients with an IChIS of 0 was 4.0 months, which was significantly longer than 1.9 months in patients with an IChIS of 1 and 1.0 month in those with an IChIS of 2 (p=0.001). The median overall survival in patients with an IChIS of 0 was 10.2 months, which was significantly longer than 6.8 and 1.8 months in patients with an IChIS of 1 and 2, respectively (p<0.001).

Conclusion: Baseline IChIS could be a potential biomarker for predicting survival benefit of immunotherapy in NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫检查点抑制剂评分（IChIS）可预测免疫疗法对非小细胞肺癌患者生存的益处。

背景：免疫检查点抑制剂（ICIs）在晚期肺癌患者中的应用日益增多。尽管目前正在进行预测 ICIs 疗效的研究，但其在临床实践中的应用仍然困难重重。因此，我们旨在通过分析血细胞特征发现一种预测标志物，并为接受 ICIs 治疗的患者开发一套评分系统：这是一项前瞻性多中心研究，研究对象是2021年6月至2022年11月接受ICIs二线治疗的晚期非小细胞肺癌（NSCLC）患者。使用自动血液分析仪对常规血样中的血细胞参数进行评估。免疫检查点抑制剂评分（IChIS）计算为中性粒细胞计数评分与未成熟粒细胞评分之和：结果：共纳入了来自 4 家机构的 143 名患者。治疗反应如下：部分反应，8.4%；病情稳定，37.1%；病情进展，44.8%。ICI治疗后的中位无进展生存期和总生存期分别为3.0个月和8.3个月。IChIS 为 0 的患者的中位无进展生存期为 4.0 个月，明显长于 IChIS 为 1 的患者的 1.9 个月和 IChIS 为 2 的患者的 1.0 个月（p = 0.001）。IChIS为0的患者中位总生存期为10.2个月，明显长于IChIS为1和2的患者，分别为6.8个月和1.8个月（P < 0.001）：基线IChIS可能是预测NSCLC免疫疗法生存获益的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊